EGFR and neoplasm: Several trials to date have shown that EGFR-TKI efficacy varies as a function of the subtype of EGFR mutation present in the target tumor, with cases harboring 19del mutations attaining greater benefits from TKI treatment relative to 21L858R cases [63–65].